Mestastop specializes in the development of proprietary platforms—METAssay, METSCAN, and METVivo—that utilize in vitro, in vivo, and patient ex vivo models to study cancer metastasis. The company addresses the critical challenge of advancing therapeutic molecules targeting metastasis, which is responsible for nearly 90% of cancer-related deaths, by enhancing the accuracy and efficiency of preclinical study designs.
Funding
₹58M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
9AACCIKMVFounders
Product
Problem
Metastasis, the spread of cancer to distant sites, is responsible for the majority of cancer-related deaths, yet developing effective therapies targeting metastasis remains a significant challenge. Traditional preclinical studies often fail to accurately predict clinical outcomes due to limitations in replicating the complexities of the metastatic process.
Solution
Mestastop provides a suite of preclinical platforms—METAssay, METSCAN, and METVivo—designed to more accurately model and study cancer metastasis using in vitro, in vivo, and patient ex vivo models. These platforms enable researchers to investigate the mechanisms of metastasis, identify novel drug targets, and evaluate the efficacy of therapeutic interventions. By leveraging a machine learning-powered approach, Mestastop aims to enhance the translatability of preclinical findings to improve the success rate of clinical trials targeting metastasis. The company's research oncology solutions support drug discovery, drug repurposing, and clinical translation.
Target Audience
Mestastop's primary customers are pharmaceutical and biotechnology companies, as well as academic research institutions, involved in cancer drug discovery and development.
Features
- METAssay: In vitro platform for high-throughput screening of compounds that inhibit metastasis-related processes.
- METSCAN: In vivo platform utilizing animal models to study the effects of therapeutic interventions on metastasis.
- METVivo: Patient ex vivo platform using patient-derived samples to evaluate drug efficacy in a personalized manner.
- Machine learning-powered analysis to identify predictive biomarkers and improve preclinical study design.
- Capabilities for identifying novel drug targets and developing companion diagnostics.